Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease. | ClinicLens
This analysis of the phase 3 TRAILBLAZER-ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p-tau217) level can reliably monitor treatment-related amyloid clearance (TRAC) after donanemab treatment in early symptomatic Alzheimer's disease (AD).
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.